JP2014500327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500327A5 JP2014500327A5 JP2013546331A JP2013546331A JP2014500327A5 JP 2014500327 A5 JP2014500327 A5 JP 2014500327A5 JP 2013546331 A JP2013546331 A JP 2013546331A JP 2013546331 A JP2013546331 A JP 2013546331A JP 2014500327 A5 JP2014500327 A5 JP 2014500327A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- motomeko
- composition according
- patient
- neurological diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 208000012902 Nervous system disease Diseases 0.000 claims 15
- 208000025966 Neurological disease Diseases 0.000 claims 11
- 102000001732 Small Leucine-Rich Proteoglycans Human genes 0.000 claims 8
- 108010040068 Small Leucine-Rich Proteoglycans Proteins 0.000 claims 8
- 230000000472 traumatic effect Effects 0.000 claims 8
- 102000004237 Decorin Human genes 0.000 claims 6
- 108090000738 Decorin Proteins 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 230000028600 axonogenesis Effects 0.000 claims 5
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 claims 4
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 claims 4
- 239000003966 growth inhibitor Substances 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 101710132601 Capsid protein Proteins 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- 108050004044 Asporin Proteins 0.000 claims 2
- 102000015827 Asporin Human genes 0.000 claims 2
- 102000004954 Biglycan Human genes 0.000 claims 2
- 108090001138 Biglycan Proteins 0.000 claims 2
- 102100032925 Chondroadherin Human genes 0.000 claims 2
- 108091013881 Epiphycan Proteins 0.000 claims 2
- 102000027313 Epiphycan Human genes 0.000 claims 2
- 102000017177 Fibromodulin Human genes 0.000 claims 2
- 108010013996 Fibromodulin Proteins 0.000 claims 2
- 206010061431 Glial scar Diseases 0.000 claims 2
- 206010018341 Gliosis Diseases 0.000 claims 2
- 101001000206 Homo sapiens Decorin Proteins 0.000 claims 2
- 102100021497 Keratocan Human genes 0.000 claims 2
- 101710153980 Keratocan Proteins 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 102000011681 Lumican Human genes 0.000 claims 2
- 108010076371 Lumican Proteins 0.000 claims 2
- 102100026632 Mimecan Human genes 0.000 claims 2
- 108091013859 Mimecan Proteins 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 102000016611 Proteoglycans Human genes 0.000 claims 2
- 108010067787 Proteoglycans Proteins 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000003376 axonal effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 108010059427 chondroadherin Proteins 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000045840 human DCN Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000269627 Amphiuma means Species 0.000 claims 1
- 108010088842 Fibrinolysin Proteins 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 238000000586 desensitisation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009207 exercise therapy Methods 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 210000004884 grey matter Anatomy 0.000 claims 1
- 208000003906 hydrocephalus Diseases 0.000 claims 1
- 230000002631 hypothermal effect Effects 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000005012 myelin Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000007658 neurological function Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 210000000225 synapse Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424769P | 2010-12-20 | 2010-12-20 | |
| US61/424,769 | 2010-12-20 | ||
| PCT/US2011/066199 WO2012088133A1 (en) | 2010-12-20 | 2011-12-20 | Methods for treating neurological conditions and compositions and materials therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500327A JP2014500327A (ja) | 2014-01-09 |
| JP2014500327A5 true JP2014500327A5 (enExample) | 2015-02-12 |
| JP5883027B2 JP5883027B2 (ja) | 2016-03-09 |
Family
ID=46235329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546331A Active JP5883027B2 (ja) | 2010-12-20 | 2011-12-20 | 神経学的疾患治療法、ならびにそのための組成物および物質 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9061047B2 (enExample) |
| EP (1) | EP2654899B1 (enExample) |
| JP (1) | JP5883027B2 (enExample) |
| AU (1) | AU2011349256B2 (enExample) |
| ES (1) | ES2582605T3 (enExample) |
| WO (1) | WO2012088133A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011349256B2 (en) | 2010-12-20 | 2017-01-05 | Scidec Therapeutics, Inc. | Methods for treating neurological conditions and compositions and materials therefor |
| WO2015089443A2 (en) * | 2013-12-12 | 2015-06-18 | The Brigham And Women's Hospital, Inc. | Treating neurodegenerative disease |
| CN104173938B (zh) * | 2014-08-29 | 2017-03-01 | 李从达 | 一种治疗脊髓栓系综合征的中药制剂 |
| GB202314158D0 (en) * | 2023-09-15 | 2023-11-01 | Senorei Ltd | Inhibition of vascular leakage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612038B2 (en) | 1999-11-18 | 2009-11-03 | Brown University | Biglycan and related therapeutics and methods of use |
| US20080140056A1 (en) | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Method for delivering large molecules to the brain |
| JP2010047533A (ja) * | 2008-08-22 | 2010-03-04 | Mitsubishi Gas Chemical Co Inc | 脊髄損傷改善剤 |
| WO2010065917A1 (en) * | 2008-12-05 | 2010-06-10 | The Regents Of The University Of California | Methods of treating neurological disorders |
| AU2011349256B2 (en) | 2010-12-20 | 2017-01-05 | Scidec Therapeutics, Inc. | Methods for treating neurological conditions and compositions and materials therefor |
-
2011
- 2011-12-20 AU AU2011349256A patent/AU2011349256B2/en active Active
- 2011-12-20 EP EP11852038.6A patent/EP2654899B1/en active Active
- 2011-12-20 ES ES11852038.6T patent/ES2582605T3/es active Active
- 2011-12-20 US US13/331,933 patent/US9061047B2/en active Active
- 2011-12-20 WO PCT/US2011/066199 patent/WO2012088133A1/en not_active Ceased
- 2011-12-20 JP JP2013546331A patent/JP5883027B2/ja active Active
-
2015
- 2015-05-18 US US14/714,626 patent/US9592276B2/en active Active
-
2017
- 2017-01-30 US US15/419,116 patent/US10258670B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | TREM2 inhibits inflammatory responses in mouse microglia by suppressing the PI3K/NF‐κB signaling | |
| Caminero et al. | Sleep disturbances in multiple sclerosis | |
| JP2009530613A5 (enExample) | ||
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2014500327A5 (enExample) | ||
| JP2016508123A5 (enExample) | ||
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112013031117A8 (pt) | Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos. | |
| RU2019110452A (ru) | Способ обеспечения требуемых уровней фактора 2 роста глии в плазме | |
| Ying et al. | Water treadmill training attenuates blood-spinal cord barrier disruption in rats by promoting angiogenesis and inhibiting matrix metalloproteinase-2/9 expression following spinal cord injury | |
| Jhun et al. | Vitamin D attenuates pain and cartilage destruction in OA animals via enhancing autophagic flux and attenuating inflammatory cell death | |
| Sassoon et al. | Positive end-expiratory airway pressure does not aggravate ventilator-induced diaphragmatic dysfunction in rabbits | |
| MX2007013876A (es) | Uso de inhibidor de la via del factor de tejido para tratar infecciones bacterianas severas. | |
| Sun et al. | Development of novel treatments for amyotrophic lateral sclerosis | |
| Davies | Unraveling the mechanisms of progressive peritoneal membrane fibrosis | |
| US20170136098A1 (en) | Methods for treating neurological conditions and compositions and materials therefor | |
| AU2011349256A1 (en) | Methods for treating neurological conditions and compositions and materials therefor | |
| de Aguiar Picanço et al. | L-arginine and glycine supplementation in the repair of the irradiated colonic wall of rats | |
| Karsdal et al. | Oral calcitonin demonstrated symptom-modifying efficacy and increased cartilage volume: results from a 2-year phase 3 trial in patients with osteoarthritis of the knee | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| Seok et al. | Transverse myelitis following combined spinal-epidural anesthesia | |
| Suarez-de-la-Rica et al. | Severe cefepime-induced status epilepticus treated with haemofiltration |